Physician profile
Daniel J Vile
NPI 1215986377
$9,670.72
in general payments reported to CMS, 2019-2025
36 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $838 · 2021: $1,465 · 2022: $1,726 · 2023: $1,605 · 2024: $1,286 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,154 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,153.64 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,123.31 | 2019-2024 | |
| Abiomed | $940.36 | 2020-2024 | Impella |
| Impulse Dynamics (USA) INC. | $782.47 | 2022-2024 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $664.06 | 2019-2024 | Xarelto |
| Canon Medical Systems USA, INC. | $638.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.75 | 2020-2025 | Jardiance |
| Amgen INC. | $545.71 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $525.59 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $521.84 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $508.71 | 2022-2025 | Symplicity G3, Corevalve Evolut R, Azure Xt Dr Mri Surescan |
| Boston Scientific Corporation | $471.21 | 2019-2024 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $326.02 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $277.58 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $224.31 | 2019-2023 | |
| Lilly USA, LLC | $174.32 | 2022-2025 | Zepbound |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $155.25 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $138.57 | 2022-2025 | Verquvo |
| Janssen Biotech, INC. | $120.80 | 2025 | Simponi Aria, Tremfya |
| Ge Healthcare | $114.69 | 2025 | |
| Abbott Laboratories | $100.34 | 2019-2024 | Mitraclip |
| Stryker Corporation | $92.74 | 2025 | Flowtriever |
| Alnylam Pharmaceuticals INC. | $88.85 | 2024-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $83.27 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $82.68 | 2025 | Purified Cortrophin Gel |
| Heartflow, INC. | $62.58 | 2025 | |
| Edwards Lifesciences Corporation | $60.70 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Biotronik INC. | $58.57 | 2021 | |
| Esperion Therapeutics, INC. | $58.09 | 2021-2024 | Nexletol |
| Althera Pharmaceuticals LLC | $36.27 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $27.03 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $25.55 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $20.21 | 2019 | |
| Philips North America LLC | $18.56 | 2022 | |
| Lantheus Medical Imaging, INC. | $17.81 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.59 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.